MedTrace Logo

Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease

NCT00154635 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2005-09-12

No results posted yet for this study

Summary

A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.

Conditions

  • Dementia, Alzheimer Type

Interventions

DRUG

DCB-AD1

Sponsors & Collaborators

  • Development Center for Biotechnology, Taiwan

    collaborator OTHER_GOV

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Program Office, National Science & Technology, Biotechnology & Pharmaceuticals

    collaborator UNKNOWN

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ming-Jang Chiu, MD, PhD · NTUH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30

Countries

  • Taiwan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154635 on ClinicalTrials.gov